| ∧ ∨ Type | ∧ ∨ Title | Principal Investigators | Status | ∧ ∨ Year |
|---|---|---|---|---|
| PRIN2015 - PRIN bando 2015 |
Neuroimmunoinfiammazione nel dolore cronico e in un modello transgenico di Alzheimer: alterazioni sensoriali e cognitivo-comportamentali e nuove prospettive terapeutiche
|
|
Closed | 2017 |
| CAR_RIC - Bandi Fondazione Cariplo |
Proprotein convertase subtilisin/kexin type 9 (PCSK9): a link between lipotoxicity, mitochondrial dysfunction, and frailty-associated heart failure
|
|
Closed | 2017 |
| FON_NAZ - Bandi Altre Fondazioni |
Patent development of the new modulators of GPR17, a key receptor in remyelinating processes
|
|
Closed | 2017 |
| INTLI - Finanziamenti internazionali |
Dissecting the role of CHD7 and SEMA3A signalling in the control of reproduction and alfaction, which are defective in CHARGE syndrome patients
|
|
Closed | 2017 |
| FON_NAZ - Bandi Altre Fondazioni |
Studi sui meccanismi molecolari e cellulari alla base della neuropatia trigeminale e della maggiore suscettibilità all'emicrania nella sclerosi multipla
|
|
Closed | 2017 |
| FON_NAZ - Bandi Altre Fondazioni |
Approfondimento e modelling dei meccanismi di rimielinizzazione indotti da antimicotici azolici in uso clinico con caratteristiche di riposizionamento.
|
|
Closed | 2017 |
| H20MCITNIF - Horizon 2020_Marie Skłodowska-Curie actions-Innovative Training Network (ITN)/Individual Fellowships (IF) |
An integrated mulTidisciplinary appRoach towards a new generAtIon of aNtibiotics: Targeting function and cross-talk of bacterial Envelope proTein machineries (Train2Target)
|
|
Closed | 2017 |
| FON_NAZ - Bandi Altre Fondazioni |
Ricerca sui tumori prostatici indolenti, invasivi e metastatici resistenti alla chemioterapia e al trattamento farmacologico
|
|
Closed | 2017 |
| PRIN2015 - PRIN bando 2015 |
Useful experimental models for dissecting the molecular links between cancer development/progression and the obesity epidemic
|
|
Closed | 2017 |
| PRIN2015 - PRIN bando 2015 |
Targeting early synaptic dysfunctions induced by alpha-synuclein as a novel therapeutic approach in Parkinson's disease
|
|
Closed | 2017 |
